Korneyev A, Pan B S, Polo A, Romeo E, Guidotti A, Costa E
Fidia-Georgetown Institute for the Neurosciences, Georgetown University, School of Medicine, Washington, D.C. 20007.
J Neurochem. 1993 Oct;61(4):1515-24. doi: 10.1111/j.1471-4159.1993.tb13647.x.
Evidence that neurosteroids are potent modulators of the action of GABA at GABAA receptors has prompted the investigation of the mechanism that controls brain neurosteroid synthesis by glial cell mitochondria in vivo. In vitro studies suggest that the interaction of the diazepam binding inhibitor (DBI)--a polypeptide that is abundant in steroidogenic cells--with glial mitochondrial DBI receptors (MDRs) is a crucial step in the physiological regulation of neurosteroid biosynthesis. MDRs bind 4'-chlorodiazepam (4'-CD), N,N-di-n-hexyl-2-(4-fluorophenyl)-indol-3-acetamide (FGIN-1-27), and the isoquinoline carboxamide PK 11195 with high affinity, and these ligands have been used to investigate whether the stimulation of glial MDRs increases brain pregnenolone production in vivo. Adrenalectomized and castrated (A-C) male rats (to eliminate peripheral sources of pregnenolone) were pretreated with trilostane (to prevent pregnenolone metabolism to progesterone), and the pregnenolone content in brain regions dissected after fixation with a 0.8-s exposure to microwave irradiation focused to the head was determined by HPLC followed by specific radioimmunoassay. The forebrain and cerebellum of A-C rats contained 4-7 ng of pregnenolone/g of tissue, and the olfactory bulb contained 10-14 ng/g. These concentrations of brain pregnenolone are only 30-40% lower than those of sham-operated rats. In contrast, the plasma pregnenolone content of sham-operated rats was 2-3 ng/ml, but it was only 0.15-0.20 ng/ml in the plasma of A-C rats. In A-C rats, treatment with the MDR ligands 4'-CD and FGIN-1-27 increased the pregnenolone content in the brain but failed to change the plasma or peripheral tissue content of this steroid. The effect of 4'-CD on brain pregnenolone content was maximal (70-100% increase) at the dose of 18 mumol/kg, 5-10 min after intravenous injection. The effect of oral administration of FGIN-1-27 on brain pregnenolone content was maximal (80-150% increase) at doses of 400-800 mumol/kg and peaked at approximately 1 h. That this effect of FGIN-1-27 was mediated by the MDR was documented by pretreatment with the MDR partial agonist PK 11195 (100 mumol/kg, i.p.). PK 11195 did not affect basal brain pregnenolone content but prevented the accumulation of brain pregnenolone induced by FGIN-1-27. FGIN-1-27 and 4'-CD failed to increase the brain concentration of dehydroepiandrosterone in A-C rats. These data suggest that glial cell MDRs play a role in neurosteroid biosynthesis in vivo.
神经甾体是γ-氨基丁酸(GABA)作用于GABAA受体的强效调节剂,这一证据促使人们对体内神经胶质细胞线粒体控制脑内神经甾体合成的机制展开研究。体外研究表明,地西泮结合抑制剂(DBI)——一种在类固醇生成细胞中大量存在的多肽——与神经胶质线粒体DBI受体(MDRs)的相互作用是神经甾体生物合成生理调节中的关键步骤。MDRs对4'-氯地西泮(4'-CD)、N,N-二正己基-2-(4-氟苯基)-吲哚-3-乙酰胺(FGIN-1-27)和异喹啉甲酰胺PK 11195具有高亲和力,这些配体已被用于研究刺激神经胶质MDRs是否会增加体内脑内孕烯醇酮的生成。对肾上腺切除和阉割(A-C)的雄性大鼠(以消除外周孕烯醇酮来源)用曲洛司坦进行预处理(以防止孕烯醇酮代谢为孕酮),在用聚焦于头部的微波照射0.8秒固定后,通过高效液相色谱(HPLC)继以特异性放射免疫测定法测定解剖的脑区中的孕烯醇酮含量。A-C大鼠的前脑和小脑中孕烯醇酮含量为4 - 7纳克/克组织,嗅球中为10 - 14纳克/克。这些脑内孕烯醇酮浓度仅比假手术大鼠低约30 - 40%。相比之下,假手术大鼠血浆中孕烯醇酮含量为2 - 3纳克/毫升,但A-C大鼠血浆中仅为0.15 - 0.20纳克/毫升。在A-C大鼠中,用MDR配体4'-CD和FGIN-1-27处理可增加脑内孕烯醇酮含量,但未能改变该类固醇的血浆或外周组织含量。静脉注射剂量为18微摩尔/千克的4'-CD,在5 - 10分钟后对脑内孕烯醇酮含量的影响最大(增加70 - 100%)。口服FGIN-1-27剂量为400 - 800微摩尔/千克时对脑内孕烯醇酮含量的影响最大(增加80 - 150%),并在约1小时达到峰值。用MDR部分激动剂PK 11195(100微摩尔/千克,腹腔注射)预处理证明了FGIN-1-27的这种作用是由MDR介导的。PK 11195不影响基础脑内孕烯醇酮含量,但可阻止FGIN-1-27诱导的脑内孕烯醇酮积累。FGIN-1-27和4'-CD未能增加A-C大鼠脑内脱氢表雄酮的浓度。这些数据表明神经胶质细胞MDRs在体内神经甾体生物合成中发挥作用。